Tangcong Chen

Tangcong Chen

Auto-generated profile, based on publicly available information

Tangcong Chen

Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University Chengdu China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Food Science & Nutrition
Verified
Journal Article
Open access
GHGang He
Gang He
TCTangcong Chen
Tangcong Chen
LHLifen Huang
Lifen Huang
YZYiyuan Zhang
Yiyuan Zhang
YFYanjiao Feng
Yanjiao Feng
WLWei Liu
Wei Liu
It has been shown that Tibetan tea (TT) inhibits obesity and controls lipid metabolism. The fundamental processes by which TT prevents obesity are yet entirely unknown. Consequently, this research aimed to ascertain if TT may prevent obesity by modifying the gut flora. Our research demonstrated that TT prevented mice from gaining weight and accumulating fat due to the high‐fat diet (HFD), decreased levels of blood total cholesterol (TC), triglycerides (TG), and low‐density lipoprotein cholesterol (LDL‐C), and raised levels of high‐density lipoprotein cholesterol (HDL‐C). Adipogenesis‐related genes such as acetyl‐Coenzyme A carboxylase 1 (ACC1, LOC107476), fatty acid synthase (Fas, LOC14104), sterol regulatory element‐binding protein‐1c (SREBP‐1c, LOC20787), CCAAT/enhancer‐binding protein α (C/EBPα, LOC12606), stearoyl‐CoA desaturase 1 (SCD1, LOC20249), and peroxisome proliferator‐activated receptor γ (PPARγ, LOC19016) had their expression downregulated by lowering the Firmicutes/Bacteroidetes (F/B) ratio and controlling the number of certain gut bacteria. TT also alleviated HFD‐induced abnormalities of the gut microbiota. The Muribaculaceae, Lachnospiraceae NK4A136_group, Alistipes, and Odoribacter families were identified as the major beneficial gut microorganisms using Spearman's correlation analysis. Fecal microbiota transplantation (FMT) demonstrated that TT's anti‐obesity and gut microbiota‐modulating benefits might be transmitted to mice on an HFD, demonstrating that one of TT's targets for preventing obesity is the gut microbiota. TT also increased the amount of short‐chain fatty acids (SCFAs) in the feces, including acetic, propionic, and butyric acids. These results indicate the possible development of TT as a prebiotic to combat obesity and associated disorders. These results suggest that TT may act as a prebiotic against obesity and its associated diseases.

22 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TCTangcong Chen
Tangcong Chen
Abbas F. AlmullaAbbas F. Almulla
Abbas F. Almulla
YLYueyang Luo
Yueyang Luo
MLMengdie Li
Mengdie Li
YHYulan Huang
Yulan Huang
MMMichael Maes
Michael Maes
Major depressive disorder (MDD) is a complex psychiatric condition characterized by immune, oxidative, and metabolic (NIMETOX) dysregulation. Using the chronic unpredictable mild stress (CUMS) mouse model, we performed untargeted LC-MS/MS metabolomic profiling on serum samples from control, CUMS-vehicle, and five pharmacologically treated groups (fluoxetine, curcumin, simvastatin, SAMe, and PDTC). A total of 2,703 metabolites were identified. CUMS was associated with significant alterations in 166 metabolites (68 up, 98 down), with KEGG enrichment revealing perturbations in vitamin B6 metabolism, aromatic amino acid biosynthesis, the pentose phosphate pathway, and cytochrome P450-mediated metabolism. Curation and recursive feature selection yielded a high-confidence panel of 68 endogenous metabolites that showed adequate cross-validated discrimination between CUMS and control mice under repeated nested five-fold cross-validation (CV-AUC = 0.999–1.000). From this panel, eight functional NIMETOX modules (M1–M8) were constructed, capturing gut-brain axis, fatty acid oxidation, redox stress, eicosanoid inflammation, phospholipid remodeling, plasmalogens, gut-liver detoxification, and neuro-myelin integrity. All five interventions partially reversed the CUMS-induced metabolomic signature, with SAMe showing the broadest restoration across six modules. However, no treatment fully normalized the metabolome toward the control state. These findings demonstrate that CUMS induces a systemic metabolic phenotype encompassing key pathways predicted by the NIMETOX model of MDD. Module-based metabolomic profiling provides a systems-level framework for dissecting stress-related metabolic dysregulation, comparing the molecular effects of mechanistically distinct interventions.